INCY
HealthcareIncyte Corporation
$101.79
+$0.37 (+0.36%)
Jan 5, 2026
Price History (1Y)
Analysis
Incyte Corporation is a biotechnology company listed in the healthcare sector with a market capitalization of $19.98 billion and approximately 2,617 employees. The company's financial health is characterized by high profitability margins, including a gross margin of 56.5%, operating margin of 31.6%, and profit margin of 24.7%. Incyte also generates substantial returns on equity (ROE) at 30.4% and return on assets (ROA) at 13.5%. The balance sheet shows low debt levels with a debt-to-equity ratio of 0.89, while cash reserves amount to $2.93 billion. In terms of valuation context, Incyte's price-to-earnings (P/E) ratio is 17.19 on a trailing-twelve-month basis and 13.30 on a forward-looking basis. The company has experienced significant revenue growth at 20.0% year-over-year, accompanied by earnings growth of 290.7%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Visit website →Key Statistics
- Market Cap
- $19.98B
- P/E Ratio
- 17.19
- 52-Week High
- $109.28
- 52-Week Low
- $53.56
- Avg Volume
- 2.25M
- Beta
- 0.82
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 2,617